We investigated the predictive value of sequential FDG PET before and after high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in 24 patients suffering from non-Hodgkin's lymphoma (NHL). FDG PET was performed at baseline, after three cycles of induction therapy, before and after HDT with ASCT. Response assessment from sequential PET scans using standardized uptake values (SUV) was available in 22 patients at the time of transplantation. Partial metabolic response (PMR) was defined as a Ͻ25% decrease of SUV between successive PET scans. Six of seven patients who did not achieve a PMR after complete induction therapy developed lymphoma progression, while 10 of 15 patients with complete metabolic response (CMR) or PMR remained in continuous remission. Four of seven patients with less than PMR after induction therapy died vs two of 15 patients with CMR/PMR. Median progression-free and overall survival of patients with less than PMR after HDT and ASCT was 9 and 29 months, respectively. In contrast, neither conventional re-staging nor the International Prognostic Index were predictive. These data suggest that sequential quantitative PET imaging does enlarge the concept of chemosensitivity used to select patients with high-risk NHL for HDT and ASCT or to route them to alternative treatments. High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) has been shown to be the best available treatment in patients who have relapsed from nonHodgkin's lymphoma (NHL) after conventional chemotherapy, but who remained chemotherapy-sensitive.
High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) has been shown to be the best available treatment in patients who have relapsed from nonHodgkin's lymphoma (NHL) after conventional chemotherapy, but who remained chemotherapy-sensitive. 1 This has prompted the use of HDT with ASCT as a front-line therapy in patients with high-intermediate or high risk disease according to the International Prognostic Index. 2 However, clinical results have been discrepant and additional prognostic factors are needed to predict final outcome of the patients at the time of transplantation.
Positron emission tomography (PET) using the glucose analogue fluorine-18-fluorodeoxglucose (FDG) has been demonstrated to improve primary staging of lymphoma and to be more precise than conventional radiological imaging for re-staging after chemotherapy. [3] [4] [5] [6] [7] Several groups including our own have reported the high predictive value of persisting abnormal FDG uptake for residual or recurrent disease in this context. [7] [8] [9] Thus FDG-PET does have a potential role in the identification of patients requiring further intensified chemotherapy. Moreover, FDG-PET can be used as a functional and quantitative measure of tumor response to induction chemotherapy 10 and may be able to differentiate between responders and non-responders at an earlier time-point than conventional CT or MRI imaging. Preliminary results in a small patient population studied before onset of treatment and again after one and two chemotherapy cycles support this hypothesis. 11 We prospectively enrolled consecutive patients with NHL who were scheduled for HDT including ASCT. Progression-free and overall survival were chosen as end points of the study. The present study was designed to show differences in detection of therapy response between conventional re-staging methods (CRS) and PET imaging and, in particular, to uncover whether semi-quantitative evaluation using the standardised uptake value (SUV) as an index of tumoral glucose consumption was superior to qualitative image interpretation. Sequential PET scanning was performed in addition to CRS at different time points covering the time from initiation of treatment to recovery from ASCT in order to analyze if sequential scans exceeded the information that could be obtained by one single PET scan and to detect the earliest time-point where prediction of patients' outcome was feasible. The EORTC recommendations for measurement of clinical and sub-clinical tumor response using FDG PET 10 were used as a guideline for the interpretation of changes in SUV during treatment.
Patients and methods

Patients and treatment
Twenty-four consecutive patients, scheduled for HDT and ASCT at the Department of Internal Medicine IV for firstline or second-line treatment of NHL, were included. Detailed patient characteristics are shown in Table 1 , histopathological lymphoma diagnosis was reviewed according to the new WHO-classification. 12 Twenty-three patients received first-line therapy and one patient suffered from relapsed lymphoma 4 years after having received HDT and ASCT as initial treatment. One patient, who progressed during induction therapy according to CRS response criteria, received further palliative treatment and had to be excluded. The results of PET imaging did not influence the clinical decision about performance of HDT in the study Autologous stem cells were re-infused on day 5. Additional involved-field radiotherapy was applied after recovery from HDT and ASCT in nine patients with either initial bulky disease or residual masses on computed tomography after transplantation and/or induction chemotherapy. As initial prognostic parameters, lactate dehydrogenase (LDH) serum levels (р240 U/l vs Ͼ240 U/l), presence or absence of bulky disease (у10 cm in longest diameter as measured by radiological imaging) and the International Prognostic Index 2 were investigated.
PET imaging
PET imaging was performed up to four times during the course of treatment parallel to conventional imaging procedures: at baseline/before initiation of induction chemotherapy (PET1), after three cycles of induction chemotherapy (PET2), after completion of induction therapy/before HDT and ASCT (PET3) and after recovery from ASCT or completion of additional involved-field radiation (PET4), that is 6 to 14 weeks after ASCT (Figure 1 ). Eighty-one PET scans were performed with dedicated full-ring scanners (Siemens ECAT Exact 922, n = 70 or Siemens ECAT 953, n = 11; Siemens-CTI, Knoxville, TN, USA) 45-75 min after i.v. injection of 150-300 MBq FDG. Imaging was usually performed from the neck to the proximal femora. In follow-up studies it was assured that acquisition protocols and imaging times were identical to the baseline study. Transmission scans for attenuation correction were available in 79/81 PET scans. Attenuation corrected images were reconstructed using iterative image reconstruction algorithms. Spatial resolution in the reconstructed images was approximately 7 mm full width at half maximum. Transversal, coronal and sagittal slices of 7 mm thickness were used for qualitative image interpretation and interpreted by an experienced nuclear medicine physician without knowledge of the findings of corresponding CRS procedures. All lesions with clearly enhanced focal glucose metabolism not explained by physiological uptake were regarded as lymphoma involvement or active lymphoma. The lesions with maximum FDG uptake were subjected to quantification of the standardized uptake value (SUV); in patients with multiple lymphoma involvement up to three lesions from different body regions were chosen as a reference. SUV was defined as decay-corrected tissue radioactivity concentration/injected dose ϫ body mass. 13 The maximum pixel value within the tumor region was used. In lesions which had visually disappeared after therapy, the region-of-interest (ROI) corresponding to the initial tumor was transferred from the earlier PET study to the followup study. ROIs representing the tumor lesions were generated semi-automatically using a software tool developed in our institution.
14 Apparent lesion diameter on PET images was 10-100 (median, 26) mm on baseline scans and 10-26 (median, 16) mm at the time of transplantation.
In patients in whom sequential PET scans were available (PET1→2, PET2→3, PET1→3 and PET3→4) a SUV decrease of more than 25% of the maximum pathological FDG uptake between first and second scan was classified as 'partial metabolic response' or 'PMR'. At the time of transplantation, PET1 was used as a baseline scan for the evaluation of PET3 only in patients, in whom PET2 was not available (PET1,2→3) as explained in Figure 1 . Based on our experience with SUV quantification in lymphoma patients prior to the current study, 9 only lesions with a maximum SUV above 3.5 were regarded as malignant. Complete resolution of former PET findings and/or SUV of all former lesions р3.5 were classified as 'complete metabolic response (CMR)'. SUV increase of more than 25% in the pathological lesion with highest uptake and/or appearance of new pathological lesions between successive PET scans was termed 'progressive metabolic disease (PMD)'. In all patients with pathological lesions which did not qualify as PMR or PMD, response was termed 'stable metabolic disease (SMD) ' .
In order to analyze the value of SUV as a potential initial prognostic parameter, patients were grouped according to the baseline SUV (SUV1) of the most active lymphoma lesion into those with SUV1 below (р22.6) or above (Ͼ22.6) the median value. In summary, we assessed PET parameters for qualitative visual interpretation (PET 1; 2; 3; 4) and for dynamic quantitative image analysis (PET1→2; PET2→3; PET1,2→3 and PET3→4).
Conventional re-staging
Conventional re-staging (CRS) consisted of clinical examination, laboratory tests, computed tomography (CT) of neck, chest and abdomen, ultrasonography and, if appropriate, magnetic resonance imaging (MRI) of the spine, bone/bone marrow scintigraphy or bone marrow biopsy. CT scans were performed at the Radiological Department of the University Hospital with use of oral and intravenous contrast agent and reviewed by an experienced radiologist (JW). Therapy response assessment with CRS was reported Bone Marrow Transplantation according to recently published guidelines for NHL 15 as complete remission (CR), complete remission unconfirmed (CRu), partial remission (PR), no change (NC) or progressive disease (PD). Bulky disease was defined as a lymphoma lesion of 10 cm or more in maximum diameter on the CT scan. 16 CRS were performed simultaneously (Ϯ1 week) to PET evaluations as shown in Figure 1 .
Statistical methods
The prognostic value of PET and CRS was evaluated by analysing progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier estimates. 17 PFS was determined as the time from stem cell transplantation to clinical lymphoma progression or last follow-up, OS as the time from transplantation to death for any reason or last follow-up. Differences in PFS and OS between subgroups defined by the different diagnostic and prognostic variables were assessed by P values resulting from log-rank tests. Due to the limited number of patients only a univariate analysis was performed. Median survival times and associated 95% confidence intervals (95% CI) were calculated. All calculations were performed with a software package for PC (SPSS for Windows, version 10.0.7, SPSS, Chicago, IL, USA).
Results
Relapse occurred in 12 patients after a time interval of 3-25 months. Estimated median PFS of all patients was 25 months (95% CI: 6-44 months). Ten relapses were documented within the first year after transplantation. Median follow-up was 30 months in surviving patients and 23 months in patients with continuous remission (range, 10-62 months). Six of the patients with progression died 7-29 months after transplantation, three of them during the first year after ASCT. All deaths were due to progressive disease; there was no mortality related to the toxicity of the treatment. Table 2 summarizes clinical data and findings of PET imaging and conventional diagnostic modalities (CRS). The prognostic value of the different variables is shown in Tables 3 and 4 . PET imaging was predictive for progression-free and overall survival at the time of transplantation, if quantitative dynamic criteria were applied (PET1,2→3). Patients who did not achieve a 'partial metabolic response' according to the aforementioned criterion of a 25% SUV decrease in subsequent PET scans during induction therapy had a reduced median PFS of 9 (95% CI: 4-14) months and a reduced median OS of 29 (95% CI: 9-49) months, in comparison to patients who fulfilled the criteria for PMR or reached a 'complete metabolic response' in PET imaging. Progress occurred in five of 15 (33%) patients with PMR or CMR before transplantation, but in six of 7 (86%) patients with less than PMR. Thus sensitivity, specificity, positive and negative predictive value of pre-transplant response assessment by PET for prediction of lymphoma progress were 55%, 91%, 86% and 67%, respectively. Death occurred in two of 15 (13%) patients who achieved at least a PMR, but in four of seven (57%) patients who did not. Kaplan-Meier plots for PFS and OS in relation to the findings of quantitative response assessment with PET before transplantation are shown in Figure 2 . A similar result was seen also in the subgroup of 14 patients, who were studied twice after three cycles of induction therapy and after completion of induction therapy (PET2→3). In patients with insufficient metabolic response between mid-induction therapy and transplantation median PFS and OS were only 5 (95% CI: 3-7) and 14 (95% CI: 9-19) months, respectively.
Ten of 11 patients fulfilled the criterion for PMR or CMR (PET1→2) termed early metabolic response. By analysis of PET1→2 therapy response in one patient was classified as 'stable metabolic disease'. Thus early restaging with PET was not predictive.
Assessment of metabolic response during high-dose chemotherapy itself (PET3→4) was also predictive for PFS and OS. Prognosis of patients with insufficient metabolic response (SUV decrease р25%) was extremely poor with a median PFS of 4 (95% CI 2-6) months and a median OS of 14 (4-24) months compared with a median PFS of 25 (95% CI 18-32) months in patients who attained PMR or CMR. However, PET imaging at this time-point was rather insensitive and only three of 12 relapses could be predicted. The predictive value of a negative PET scan shortly after transplantation was only 56%, which means that seven of 16 patients with a CMR finding developed progression later on.
Qualitative interpretation of PET scans was used to differentiate patients with complete metabolic remission (absence of pathological tumor lesions) and those without CMR (presence or persistence of tumor lesions, respectively). Qualitative interpretation (PET1-4) seemed not to be of relevant prognostic value at any of the investigated time points. Conventional re-staging (CRS) was not able to predict patient outcome in the current study, either. The four putative prognostic factors assessed at the time of initial diagnosis (International Prognostic Index, presence of bulky disease, elevated LDH plasma level and elevated SUV of untreated lymphoma) also were not predictive of final outcome. However, only seven patients belonged to the subgroup with high or high-intermediate IPI. Two of these patients failed to achieve a PMR in PET before transplantation; both relapsed and died. In contrast, among the five patients who had attained PMR at the time of HDT and ASCT three remained in remission and only one died.
Application of external radiotherapy after recovery from HDT and ASCT in nine patients was not a decisive prognostic factor. Four of 15 patients not receiving radiotherapy died during follow-up, as did two of nine patients who received radiotherapy (P = 0.95). Progress occurred in nine patients not receiving radiotherapy and in three patients after radiotherapy (P = 0.39). ; LDH = lactate dehydrogenase; SUV = standardised uptake value; CRS = conventional re-staging (PR = partial remission, CR(u) = complete remission (unconfirmed)); CMR = complete metabolic remission; PMR = partial metabolic remission; 'Ͻ' = 'less than'; 'у' = 'at least'; PFS = progression free survival; CI = confidence interval.
A typical PET finding of a residual mass showing persistent FDG uptake is demonstrated in Figure 3 . In this patient, PET was also used during further follow-up after ASCT and allowed detection of relapse at an early disease stage in conjunction with the CT scan. A typical effect of the therapy itself on FDG uptake and glucose metabolism, respectively, is demonstrated in Figure 4 . Stimulation of the bone marrow during recovery of hematopoiesis from chemotherapy and application of hematopoietic growth factors resulted in diffuse and intense bone marrow uptake, while the uptake of abdominal lymphoma had clearly decreased compared to the baseline study.
Discussion
Several authors have recently reported on the prognostic value of FDG PET imaging in patients treated for nonHodgkin's lymphoma, [6] [7] [8] [9] but to our knowledge the present study is one of the first two reports that demonstrate the ability of PET scanning with FDG to predict outcome of patients suffering from NHL treated by high-dose chemotherapy and autologous stem cell transplantation as soon as the time of transplantation. Another report on this issue has been published recently. Becherer et al 18 
investigated the
Bone Marrow Transplantation predictive value of FDG PET in 16 patients (10 with NHL and six with Hodgkin's disease) before HDT and stem cell transplantation. However, in contrast to our report their patients were selected retrospectively from a larger database of 236 lymphoma patients who underwent PET imaging for various reasons and baseline scans were available for comparison in 11 patients only.
The strength of PET in the present study lies in its high positive predictive value for treatment failure after HDT and ASCT in patients who failed to achieve at least a partial metabolic response at the end of induction chemotherapy according to the criteria suggested by the EORTC functional imaging group in 1999. 10 This was most clearly observed in the patients, who were also studied after three cycles of induction therapy, thus allowing explicit metabolic response assessment of the late phase of induction therapy. In this subgroup median PFS was 3-7 months and median OS 9-19 months in patients who did not achieve at least partial metabolic response. Interestingly, a similar prognostic value was not obtained during the early phase of induction therapy, when all patients except one attained a partial metabolic response with PET. This underlines the biologic importance of a sustained response to induction chemotherapy.
The sensitivity of PET scans to predict lymphoma pro- a Log-rank test (P values below 0.1 in bold). b 2→3 or 1→3 in patients, in whom 2→3 was not available. IPI = International Prognostic Index (L = low risk, LI = low intermediate risk, H = high risk, HI = high intermediate risk); LDH = lactate dehydrogenase; SUV = standardised uptake value; CRS = conventional re-staging (PR = partial remission, CR(u) = complete remission (unconfirmed)); CMR = complete metabolic remission; PMR = partial metabolic remission; 'Ͻ' = 'less than'; 'у' = 'at least'; OS = overall survival; CI = confidence interval.
gression and hence to detect the presence of residual or minimal residual disease was rather poor among our patients. Only approximately half of the relapses were predicted by pre-transplant PET imaging. Five patients progressed, although PET imaging had shown complete metabolic response after induction therapy. After transplantation sensitivity of PET imaging was even poorer, seven of 12 patients who progressed during the further course remained undetected. This is in line with published data on sensitivity, specificity and predictive values of FDG PET after conventional first-line chemotherapy of lymphoma patients.
Positive predictive values of 80-100% and negative predictive values of 83-89% were reported in this setting, sensitivity varied from 43 to 88%. [5] [6] [7] In our study, three of the five patients in whom residual disease remained undetected by PET at the time of transplantation, suffered from follicular lymphoma of grade 1 or with secondary transformation to grade 3. Three of these patients (1, 3 and 15 in Table  2 ) achieved a second stable remission with a duration of 44, 34 and 16 months after relapse and second-line therapy. In one patient with secondary transformed lymphoma biopsy at the site of relapse showed low-grade lymphoma only. FDG uptake in NHL has been described to correlate well with lymphoma grading. 19 Thus it seems reasonable to assume that in NHL containing high-grade and low-grade components, PET will preferably assess the therapy response of high-grade components, while low-grade components may escape detection. This may also be the reason for higher sensitivity of PET in the study of Becherer et al, 18 because only one patient among their study population had low-grade NHL.
The only variable of prognostic relevance offered by conventional diagnostic modalities that has been identified so far as an adverse risk factor at the time of transplantation in NHL patients, is a residual mass of 10 cm diameter or more. 16 In the same report, chemoresistance was only of borderline significance among a retrospective multivariate analysis of different variables. However, the data of the present study imply that chemoresistance as evidenced by metabolic response (PET2→3) may be of major prognostic importance. Up to now chemoresistance during induction therapy may not have been assessed well enough due to the well-known 'residual mass' problem blinding morphologyorientated radiological imaging against small volume changes of viable tumor within partly necrotic or fibrotic residual masses.
For the planning of future trials in lymphoma patients and for the cost-effective use of PET scanning in NHL patients our study provides several important implications. It seems that at least two PET scans are necessary to gain the optimal information about metabolic response for prediction of outcome. In patients who undergo five to seven courses of induction chemotherapy, a first scan should be performed after three therapy cycles and a second scan after completion of the therapy scheme. Qualitative image interpretation must be complemented by a quantitative analysis of FDG uptake in all relevant tumor lesions. In this respect semi-quantitative calculation of the standardized uptake value as an index of glucose metabolism seems sufficient. Quantification of SUV has the advantage of simple performance during routine whole-body PET imaging over more sophisticated methods. Only transmission scanning to measure photon attenuation and correct scanner calibration have to be provided and imaging protocols have to be kept constant between baseline and followup studies. 10, 13 An appropriate imaging protocol is practised in our institution as a routine in all tumour patients for several years.
Baseline scans and baseline SUV before the initiation of treatment had no additive prognostic value in the present Bone Marrow Transplantation study and may be skipped in NHL patients, especially if advanced stage is already shown by other modalities. PET scans after transplantation did not have additive prognostic value either compared with pre-transplant scans and may be clinically of minor importance because therapeutic options are usually limited shortly after HDT and ASCT. In addition, sensitivity and negative predictive value of PET seemed to be lower than before HDT and ASCT, probably due to stunning effects leading to transient reduction of tumoral glucose metabolism shortly after intense therapy.
Among all procedures used to evaluate initial tumor burden and subsequently response to treatment we have been able to identify sustained metabolic response as determined by PET2→3 and PET1,2→3 as the most promising prognostic variable at the time of transplantation. Sustained response to antineoplastic treatment has long been considered to be a crucial element of all curative strategies in mathematical models of combination chemotherapy. Metabolic response as derived from sequential PET studies may well be the appropriate way to assess patients for such sustained response in a clinical setting. Our study has not been designed to prove that sequential PET studies will in fact have a decisional impact on treatment policy and save patients from unnecessary toxicity by HDT. The very poor outcome for patients who failed to achieve such sustained metabolic response, however, does enlarge the concept of chemosensitivity as a prognostic variable and should help to route such patients to other forms of treatment.
The present study has several limitations. The fact that not all scheduled PET scans could be carried out in every patient at the time of therapy initiation and at early re-staging reflects the conflict between the clinician's need for a swift flow of diagnostic and therapeutic procedures and the clinical reality of a busy clinical and research PET center with sometimes limited flexibility concerning the appointment of scans.
Due to the small number of patients and the different subtypes of NHL included, the conclusions must remain preliminary. Nevertheless, the statistical analysis is reasonable to explore the effects among the different variables and to estimate the diagnostic value of the parameters for the planning of future studies. These studies in a larger number of patients must confirm our present observations. Such larger studies may also be used to define the cut-off criteria for response assessment with PET in NHL more precisely and to take into account the different a priori prognosis described by the IPI.
PET assessment of the bone marrow early after chemotherapy is severely impeded by the fact that hematopoietic recovery is accompanied by a strong stimulation of glucose uptake throughout the active marrow, especially after the application of hematopoietic growth factors. 20 This could also be shown in our patients (Figure 4 ), but it was of minor importance for the present study, because we did not take diffuse bone marrow uptake as a reference and all of our patients had at least one reference lesion outside the bone marrow. However, it may be a relevant problem in patients with primary osseous lymphoma.
PET evaluations of hot spot tumor foci which are small in comparison to the resolution of the imaging device are known to underestimate the quantitative radiotracer uptake due to the partial volume effect. In agreement with the literature, 21 phantom experiments of our group with the PET scanners used in the present study showed that maximum SUVs of lesions above 15 mm diameter reflect true radioactivity concentrations, while FDG uptake in smaller lesions is underestimated, thus also affecting quantification of the smallest (10-15 mm) lesions in the present study.
In addition, involved-field radiotherapy applied in some of our patients for consolidation after transplantation may be a confounding factor. However, application of radiotherapy was not found to be a significant prognostic factor in our study population.
